Boston Scientific announces recall of Lotus Valve devices

By |February 24th, 2017|Opinions|

Boston Scientific Corporation ($BSX) announced that it plans to recall its Lotus Valve devices due to reports of a premature release of a pin connecting the valve to the delivery system. The problem is most likely caused by excess tension in the pin mechanism introduced during the manufacturing process. The [...]

Premarket Biotech Digest – $PTX reports +ve results, $AOLS starts Phase I, $AGEN flunks study

By |February 24th, 2017|Digest|

OncoSec Medical Inc. ($ONCS) announced new positive clinical data from a Phase II Investigator Sponsored Trial assessing the combination of OncoSec's investigational intratumoral therapy, ImmunoPulse® IL-12, and the approved anti-PD- 1 therapy (pembrolizumab), in patients with unresectable metastatic melanoma. The results ndicated that ImmunoPulse® [...]

HealthSouth announces strong quarterly results, provides guidance

By |February 23rd, 2017|Opinions|

HealthSouth Corp ($HLS) recently reported its quarterly numbers. Its earnings for the quarter stood at $0.72 per share, beating consensus estimates of $0.63 per share in earnings. The company’s revenue for the quarter stood at $949.9 million, lagging behind estimates of $955.6 million. The company also provided results for its [...]

Premarket Biotech Digest – $PPHM stock shoots up, $AEMD reports +ve trial results, $HTGM receives delisting notice

By |February 23rd, 2017|Digest|

Aethlon Medical Inc. ($AEMD) announced the results of its study seeking to validated the in vitro capture of Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. The results validated the ability of the Aethlon Hemopurifier® to capture latent [...]

Lantheus reports Q4 results, new deal with GE

By |February 22nd, 2017|Opinions|

Lantheus Holdings Inc. (NASDAQ:LNTH) reported its financial results for the fourth quarter and full year 2016. It also provided guidance for the current year. The company’s revenue during the fourth quarter stood at 74.4 million, compared to $71.2 million for the fourth quarter of 2015. For the full year 2016, [...]

Premarket Biotech Digest – $DCTH inks new deal, $HLS reports quarterly results, $ABT announces notes exchange

By |February 22nd, 2017|Digest|

HealthSouth Corp ($HLS) stock gained over 2 percent in its Tuesday trading session as the company reported its quarterly numbers. Its earnings for the quarter stood at $0.72 per share, beating consensus estimates of $0.63 per share in earnings. The company’s revenue for the [...]

Cellect Biotechnology reports positive results for ApoGraft trial

By |February 21st, 2017|Opinions|

Cellect Biotechnology ($APOP) shot up 14 percent in the current trading session as the company announced positive results from its clinical trial of ApoGraft™ in healthy donors. The primary objective for the study was to validate the Company's propriety method of stem cell selection by going through the process of [...]

Cellect Biotechnology reports positive results for ApoGraft trial

By |February 21st, 2017|Digest|

Cellect Biotechnology ($APOP) shot up 14 percent in the current trading session as the company announced positive results from its clinical trial of ApoGraft™ in healthy donors. The primary objective for the study was to validate the Company's propriety method of stem cell selection by going through the process of [...]

Premarket Biotech Digest – $VCEL receives FDA nod, $SRPT sells FDA voucher, $TRVN reports +ve results

By |February 21st, 2017|Digest|

Premarket Biotech Digest – $VCEL receives FDA nod, $SRPT sells FDA voucher, $TRVN reports +ve results $Digest, $VCEL, $SRPT, $TRVN Sarepta Therapeutics ($SRPT) announced selling an FDA review voucher to Gilead Sciences. The deal is expected to be worth $125 million. The company had [...]

Gilead Sciences receives Canadian approval for HIV drug

By |February 20th, 2017|Opinions|

Gilead Sciences Inc. ($GILD) announced that it has received approval in Canada for its ODEFSEY for treating HIV-1 infection. ODEFSEY is indicated in Canada as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) [...]

Premarket Biotech Digest – $BSX provides estimates, $PODD reports +ve outcome, $ARQL flunks trial

By |February 20th, 2017|Digest|

Momenta Pharmaceuticals ($MNTA) reported a potential hurdle in an application for its Glatopa products. The company said that Sandoz’s contracted fill/finish manufacturing partner, Pfizer, has received an FDA warning letter. The Pfizer facility is a key part of the supply chain for the Company’s [...]

AstraZeneca reports positive Phase 2 results for cancer drug

By |February 17th, 2017|Opinions|

AstraZeneca ($AZN) achieved an important milestone as the company announced that its Phase III OlympiAD trial comparing LYNPARZA™ (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations met its [...]

Premarket Biotech Digest – $VRX receives FDA approval, $GLD reports new deal, $XBIT meets endpoints

By |February 17th, 2017|Digest|

Gilead Sciences Inc. ($GILD) announced that it has received approval in Canada for its ODEFSEY for treating HIV-1 infection. ODEFSEY is indicated in Canada as a complete regimen for the treatment of adults infected with HIV-1 with no known mutations associated with resistance to [...]

Cryolife Inc. announces strong Q4 and financial year results

By |February 16th, 2017|Opinions|

Cryolife Inc. ($CRY) stock jumped over 4 percent in its post-trading session as the company announced its fourth quarter and full year results for 2016. The company reported 13 percent Year over Year increase in its revenue to $45 million for the fourth quarter. The increase was mainly due to [...]

Premarket Biotech Digest – $PLX provides updates, $MRK stops trial, $IART acquires new business

By |February 16th, 2017|Digest|

Our App Is Updated, Install it here Point your mobile browser to this link - https://gonative.io/share/wexpwj Download the APK for Android (Apple doesn't work yet), ignore the warning messages if any, and install it. Intellia Therapeutics ($NTLA) stock slumped over 9 percent in its [...]

CIGNA terminates deal with Anthem, to sue for damages

By |February 15th, 2017|Opinions|

CIGNA Corporation ($CI) announced that it has terminated its merger agreement with Anthem. The health insurer had $48 billion acquisition offer from Anthem. On February 8th, the U.S. District Court for the District of Columbia granted the U.S. Department of Justice’s request to block Anthem’s acquisition of Cigna. The Anthem [...]

Premarket Biotech Digest – $NVAX restarts clinical trial, $AET terminates merger, $IONS gets milestone payment

By |February 15th, 2017|Digest|

Our Android App Is Updated, Install it here Point your mobile browser to this link - app Download the APK for Android (Apple doesn't work yet), ignore the warning messages if any, and install it. Aetna Inc. ($AET) announced that its proposed merger with [...]

Inovio Inks new deal with ApolloBio Corporation

By |February 14th, 2017|Opinions|

Inovio Pharmaceuticals Inc. ($INO) announced its new collaboration with ApolloBio Corporation. The new pact deals with providing ApolloBio with the exclusive right to develop and commercialize VGX-3100, which is Inovio’s DNA immunotherapy product designed to treat pre-cancers caused by human papillomavirus (HPV). ApolloBio will have commercializing rights within Greater China [...]

Premarket Biotech Digest – $ZLTQ to be acquired, $CUTR reports results, $ANTM gets buy rating

By |February 14th, 2017|Digest|

Cutera Inc. ($CUTR) reported its fourth quarter and full financial year results. The company reported 26 percent increase in its revenue for the fourth quarter to a record $37.9 million, due primarily to a 45% growth in North American product revenue. This is the [...]

Sage Therapeutics reports positive results from a Phase 2 trial

By |February 13th, 2017|Opinions|

Sage Therapeutics ($SAGE) announced top line data from its Phase 2 clinical trial of orally-administered SAGE-217 for the treatment of major depressive disorder. The primary endpoint of the 13 patient Part A open-label trial was to evaluate safety and tolerability. SAGE-217 was found to be generally well-tolerated with no serious [...]

s2Member®